Dimensional Fund Advisors LP grew its position in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 1.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 447,357 shares of the medical research company’s stock after purchasing an additional 6,803 shares during the quarter. Dimensional Fund Advisors LP’s holdings in PRA Health Sciences were worth $41,134,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. lifted its position in shares of PRA Health Sciences by 1.4% during the 4th quarter. BlackRock Inc. now owns 6,158,867 shares of the medical research company’s stock valued at $566,369,000 after buying an additional 84,557 shares during the last quarter. Vanguard Group Inc lifted its position in shares of PRA Health Sciences by 12.8% during the 3rd quarter. Vanguard Group Inc now owns 5,811,972 shares of the medical research company’s stock valued at $640,421,000 after buying an additional 658,191 shares during the last quarter. FMR LLC lifted its position in shares of PRA Health Sciences by 11.7% during the 4th quarter. FMR LLC now owns 2,588,853 shares of the medical research company’s stock valued at $238,071,000 after buying an additional 271,360 shares during the last quarter. Pendal Group Ltd purchased a new position in shares of PRA Health Sciences during the 4th quarter valued at $70,530,000. Finally, Jennison Associates LLC lifted its position in shares of PRA Health Sciences by 3.9% during the 4th quarter. Jennison Associates LLC now owns 866,731 shares of the medical research company’s stock valued at $79,705,000 after buying an additional 32,581 shares during the last quarter. 99.09% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ:PRAH opened at $89.05 on Monday. The company has a debt-to-equity ratio of 0.97, a quick ratio of 0.90 and a current ratio of 0.90. PRA Health Sciences Inc has a 52-week low of $80.28 and a 52-week high of $121.98. The firm has a market cap of $5.85 billion, a P/E ratio of 22.66, a P/E/G ratio of 1.16 and a beta of 1.01.
PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings data on Wednesday, February 27th. The medical research company reported $1.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.18 by $0.03. PRA Health Sciences had a return on equity of 26.87% and a net margin of 5.50%. The company had revenue of $729.65 million for the quarter, compared to analyst estimates of $750.67 million. Research analysts forecast that PRA Health Sciences Inc will post 4.63 earnings per share for the current year.
A number of research analysts have recently commented on PRAH shares. Robert W. Baird upped their price target on PRA Health Sciences from $119.00 to $122.00 and gave the company an “outperform” rating in a research report on Thursday, February 28th. BidaskClub cut PRA Health Sciences from a “hold” rating to a “sell” rating in a research report on Friday, April 19th. Wolfe Research started coverage on PRA Health Sciences in a research report on Tuesday, April 2nd. They set a “market perform” rating on the stock. ValuEngine cut PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, April 13th. Finally, SunTrust Banks upped their price target on PRA Health Sciences to $120.00 and gave the company an “average” rating in a research report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $113.22.
ILLEGAL ACTIVITY WARNING: “Dimensional Fund Advisors LP Purchases 6,803 Shares of PRA Health Sciences Inc (PRAH)” was first published by Zolmax and is the sole property of of Zolmax. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://zolmax.com/investing/dimensional-fund-advisors-lp-purchases-6803-shares-of-pra-health-sciences-inc-prah/3096526.html.
PRA Health Sciences Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Further Reading: Why is insider trading harmful?
Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.